These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 9563066)

  • 1. Localized delivery of proteins in the brain: can transport be customized?
    Haller MF; Saltzman WM
    Pharm Res; 1998 Mar; 15(3):377-85. PubMed ID: 9563066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of nerve growth factor following direct delivery to brain interstitium.
    Krewson CE; Klarman ML; Saltzman WM
    Brain Res; 1995 May; 680(1-2):196-206. PubMed ID: 7663977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotrophin delivery using nanotechnology.
    Angelova A; Angelov B; Drechsler M; Lesieur S
    Drug Discov Today; 2013 Dec; 18(23-24):1263-71. PubMed ID: 23891881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion of epidermal growth factor in rat brain extracellular space measured by integrative optical imaging.
    Thorne RG; Hrabetová S; Nicholson C
    J Neurophysiol; 2004 Dec; 92(6):3471-81. PubMed ID: 15269225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nerve growth factor delivery systems.
    Haller MF; Saltzman WM
    J Control Release; 1998 Apr; 53(1-3):1-6. PubMed ID: 9741908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport and elimination of recombinant human NGF during long-term delivery to the brain.
    Krewson CE; Saltzman WM
    Brain Res; 1996 Jul; 727(1-2):169-81. PubMed ID: 8842395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
    Popovic N; Brundin P
    Int J Pharm; 2006 May; 314(2):120-6. PubMed ID: 16529886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential distribution of exogenous BDNF, NGF, and NT-3 in the brain corresponds to the relative abundance and distribution of high-affinity and low-affinity neurotrophin receptors.
    Anderson KD; Alderson RF; Altar CA; DiStefano PS; Corcoran TL; Lindsay RM; Wiegand SJ
    J Comp Neurol; 1995 Jun; 357(2):296-317. PubMed ID: 7665731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoneurotherapeutics approach intended for direct nose to brain delivery.
    Md S; Mustafa G; Baboota S; Ali J
    Drug Dev Ind Pharm; 2015; 41(12):1922-34. PubMed ID: 26057769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of nose-brain delivery of therapeutic agents for treating neurodegenerative diseases using peppermint oil.
    Vaka SR; Murthy SN
    Pharmazie; 2010 Sep; 65(9):690-2. PubMed ID: 21038847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled epi-cortical delivery of epidermal growth factor for the stimulation of endogenous neural stem cell proliferation in stroke-injured brain.
    Cooke MJ; Wang Y; Morshead CM; Shoichet MS
    Biomaterials; 2011 Aug; 32(24):5688-97. PubMed ID: 21550655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving drug delivery technology for treating neurodegenerative diseases.
    Choonara YE; Kumar P; Modi G; Pillay V
    Expert Opin Drug Deliv; 2016 Jul; 13(7):1029-43. PubMed ID: 26967508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioengineered sequential growth factor delivery stimulates brain tissue regeneration after stroke.
    Wang Y; Cooke MJ; Sachewsky N; Morshead CM; Shoichet MS
    J Control Release; 2013 Nov; 172(1):1-11. PubMed ID: 23933523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.
    Yang W; Barth RF; Adams DM; Ciesielski MJ; Fenstermaker RA; Shukla S; Tjarks W; Caligiuri MA
    Cancer Res; 2002 Nov; 62(22):6552-8. PubMed ID: 12438250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CNS transporters for treatment of neurodegenerative diseases.
    Jedlitschky G; Grube M; Mosyagin I; Kroemer HK; Vogelgesang S
    Curr Pharm Des; 2014; 20(10):1523-33. PubMed ID: 23789959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma nerve growth factor access to the postnatal central nervous system.
    Fabian RH; Hulsebosch CE
    Brain Res; 1993 May; 611(1):46-52. PubMed ID: 8518950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration.
    Skaper SD; Walsh FS
    Mol Cell Neurosci; 1998 Nov; 12(4-5):179-93. PubMed ID: 9828084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular Nerve Growth Factor (NGF) and NGF Eye Drop Application as Paradigms to Investigate NGF Neuroprotective and Reparative Actions.
    Tirassa P; Rosso P; Iannitelli A
    Methods Mol Biol; 2018; 1727():19-38. PubMed ID: 29222770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanostructure-based drug delivery systems for brain targeting.
    Haque S; Md S; Alam MI; Sahni JK; Ali J; Baboota S
    Drug Dev Ind Pharm; 2012 Apr; 38(4):387-411. PubMed ID: 21954902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.